Product Description
an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure (Sourced from: https://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.6b00122)
Mechanisms of Action: ROMK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Heart Failure|Kidney Diseases|Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| MK-7145-011 | P1 |
Terminated |
Heart Failure|Kidney Diseases |
2014-12-17 |
2022-05-04 |
Primary Endpoints|Treatments |
|
| MK-7145-018 | P1 |
Withdrawn |
Kidney Diseases |
2013-12-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
| MK-7145-009 | P1 |
Completed |
Hypertension |
2011-12-19 |
2022-05-04 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|